Focus: Vanda is a public specialty pharma company focused on neurology and sleep disorders, headquartered in Washington, DC. They commercialize three marketed products generating ~$193M in annual revenue with a 40% R&D intensity.
Profile data last refreshed Yesterday · AI intelligence enriched 2mo ago
No open roles listed right now. Follow Vanda Pharmaceuticals to get notified when they start hiring — the background below is worth knowing for when they do.
Help build intelligence for Vanda Pharmaceuticals
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Vanda Pharmaceuticals's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Flagship revenue driver (46% of total) treating rare circadian rhythm disorders; strong patent protection through 2041 but faces generic competition from ANDA filers.
Second-largest revenue contributor (48% combined with HETLIOZ); atypical antipsychotic with longer patent tail than HETLIOZ but earlier LOE exposure (2031).
S1P receptor modulator with lower commercial penetration; represents diversification into autoimmune but contributes <5% of revenue.
2 discontinued, 4 duplicate formulations not shown
Vanda Pharmaceuticals stock (US92178N1054): FDA decision and legal battle keep investors on edge - AD HOC NEWS
Vanda Pharmaceuticals stock (US92178N1054): FDA decision and legal battle keep investors on edge AD HOC NEWS
Vanda Pharmaceuticals stock (US92178N1054): Regulatory setback, sharp drop and rising short interest - AD HOC NEWS
Vanda Pharmaceuticals stock (US92178N1054): Regulatory setback, sharp drop and rising short interest AD HOC NEWS
Vanda Pharmaceuticals Reports First Quarter 2026 Financial Results - PR Newswire
Vanda Pharmaceuticals Reports First Quarter 2026 Financial Results PR Newswire
D.C.'s Vanda Pharmaceuticals launches first new prescription motion sickness drug in decades - The Business Journals
D.C.'s Vanda Pharmaceuticals launches first new prescription motion sickness drug in decades The Business Journals
Vanda Pharmaceuticals Announces U.S. Commercial Availability of NEREUS™ (tradipitant), the First New Pharmacologic Treatment for People with Motion Sickness in More Than 40 Years - PR Newswire
Vanda Pharmaceuticals Announces U.S. Commercial Availability of NEREUS™ (tradipitant), the First New Pharmacologic Treatment for People with Motion Sickness in More Than 40 Years PR Newswire
[ARS] Vanda Pharmaceuticals Inc. SEC Filing - Stock Titan
[ARS] Vanda Pharmaceuticals Inc. SEC Filing Stock Titan
Showing 6 of 10 news items
No open positions listed yet. Check their careers page directly.
Based on last 3 crawl cycles
Source: USCIS H-1B Employer Data Hub
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo